A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis - BEACON OLE

Sato Toshiyuki0 个研究点目标入组 21 人开始时间: 2023年10月24日最近更新: 2023年11月20日

试验速览

阶段: 2 期
状态: 招募中
发起方
入组人数: 21

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 18age old 至 <= 75age old（—）
性别: All

入选标准

•1. Written informed consent.
•2. Completed the double-blind Treatment Period (Week 52) in Trial HZNP-HZN-825-301; subjects prematurely discontinued from trial drug in Trial HZNP-HZN-825-301 for reasons other than safety or toxicity can be included at the discretion of the Investigator after completing Trial HZNP-HZN-825-301 scheduled visits, including Week 52 assessments.
•3. Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the trial.

排除标准

•1. Anticipated use of another investigational agent for any condition during the course of the trial.
•2. New diagnosis of malignant condition after enrolling in Trial HZNP-HZN-825-301 (except successfully treated basal/squamous cell carcinoma of the skin or cervical cancer in situ).
•3. Women of childbearing potential (WOCBP) or male subjects not agreeing to use highly effective method(s) of birth control throughout the trial and for 4 weeks after last dose of trial drug. Male subjects must refrain from sperm donation and females from egg/ova donation for this same time period. Women are considered of childbearing potential if they are not postmenopausal and not surgically sterile (documented bilateral salpingectomy, bilateral oophorectomy or hysterectomy). A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle-stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. Fertile male subjects must use a condom throughout the trial and for 4 weeks after the last dose of trial drug. A man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy.
•4. Pregnant or lactating women.
•5. Any new development with the subject's disease or condition or any significant laboratory test abnormality during the course of Trial HZNP-HZN-825-301 that, in the opinion of the Investigator, would potentially put the subject at unacceptable risk.
•6. Subjects will be ineligible if, in the opinion of the Investigator, they are unlikely to comply with the trial protocol or have a concomitant disease or condition that could interfere with the conduct of the trial.

研究者

发起方

Sato Toshiyuki

相似试验

招募中

1 期

A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic SclerosisDiffuse Cutaneous Systemic SclerosisMedDRA version: 21.0Level: LLTClassification code 10042953Term: Systemic sclerosisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders

EUCTR2021-006271-42-DEHorizon Therapeutics Ireland DAC240

招募中

1 期

EUCTR2021-006271-42-ATHorizon Therapeutics Ireland DAC240

招募中

1 期

EUCTR2021-006271-42-PLHorizon Therapeutics Ireland DAC240

已完成

2 期

A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis

2023-509783-23-00Horizon Therapeutics Ireland Designated Activity Company167

进行中（未招募）

1 期

A Multicenter, Open-label Extension Trial to Assess the Long-term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects with Partial-onset Seizures Ensayo de extension abierto multicentrico para evaluar el uso a largo plazo de la monoterapia con lacosamida y la seguridad de la momoterapia y el tratamiento complementario con lacosamida en pacientes con crisis parcialesPartial-onset seizures (with and without secondary generalization) Crisis parciales ( con o sin generalización secundaria)

EUCTR2007-005440-25-ESSCHWARZ BIOSCIENCES, Inc.322